OREGON HEALTH & SCIENCE UNIVERSITY for OREGON HEALTH & SCIENCE UNIVERSITY
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Maintaining the current charitable tax deduction.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Health Issues HCR
Adequacy of health care workforce associated with expansion of health care coverage.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Veterans VET
Access to care for veterans and physician workforce issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Animals ANI
Use of animals in biomedical research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Medicare/Medicaid MMM
Preventing cuts to Medicare Graduate Medical Education payments: The Medicare IME Pool Act of 2015 (H.R. 3292); preventing cuts to Disproportionate Share Hospital Payments: The Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015 (H.R. 3288); Preventing reductions to Hospital Inpatient and Outpatient PPS Payments: The Medicare Crosswalk Hospital Code Development Act of 2015 (H.R. 3291), Section 603 Bipartisan Budget Act of 2015 (1314); Provider reimbursements for end of life care counseling; Additional Medicare support for Medicare Graduate Medical Education; Allowing nurse practitioners, certified nurse-midwives, and clinical nurse specialists to certify home health services for Medicare patients: "Home Health Care Planning Improvement Act (S 578); Medicare payment for short hospital stays; Preventing reductions to the Medicaid program including the provider tax; Improvements to the Medicaid program for medically complex children: "Advancing Care for Exceptional Children Act of 2015" (HR 546/S 298).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Pharmacy PHA
340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Copyright/Patent/Trademark CPT
Protecting innovators from frivolous patent lawsuits: "Innovation Act" (HR 9).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Budget/Appropriations BUD
FY 2016 funding for NIH, Title VII and VIII of the Public Health Services Act, Centers for Disease Control, Agency for HealthCare Research and Quality, Healthcare Resources and Services Administration, Office of Refugee Resettlement; Maternal Child Health Bureau: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 (HR 3020/S 1695); FY2016 funding for National Science Foundation, NOAA's Integrated Ocean Observing System: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2016 (HR 2578); FY 2016 funding for USGS Columbia River program: Department of the Interior, Environment, and Related Agencies Appropriations Act, 2016 (S 1645); FY 2016 funding for Department of States Bureau of Oceans and International Environmental and Scientific Affairs: Department of State, Foreign Operations, and Related Programs Appropriations Act, 2016 (S 1725); FY 2016 funding for Department of Defense Health Research and for biomarkers research, lung injury research, spinal cord injury and vaccine development for malaria, dengue virus and chikungunya virus: Department of Defense Appropriations Act, 2016 (S 1558); FDA regulation of mitochondrial replacement therapy: Section 749 in Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 (HR 3049); The Consolidated Appropriations Act, 2016 (HR 2029)
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Medical/Disease Research/Clinical Labs MED
Impact of Budget Control Act of 2011's Sequestration on medical research; use of animals in biomedical research; moving medical research from bench to bedside more quickly including greater sharing of research data, reducing administrative burden on medical researchers, streamlining of clinical trials, increased flexibility in the FDAs approval processes for drugs and devices tied with additional review in post-market: 21st Century Cures Act (HR 6); FDA regulation of mitochondrial replacement therapy: Section 749 in Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 (HR 3049), The Consolidated Appropriations Act, 2016 (HR 2029).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LYNNE DAVIS BOYLE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.